Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 13, 2005. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,500,000 ordinary shares of 25 pence each.
- Purchase Price: 1,446.43 pence per share.
- Treasury Holdings: 137,008,000 shares held in Treasury following the transaction.
- Shares in Issue: 5,822,664,152 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares and the increase in Treasury stock resulting from the open market purchase executed on December 13, 2005. This action was authorized by shareholders at the Annual General Meeting on May 25, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Points
- Verify the total cost of the repurchase by multiplying the 1,500,000 shares by the 1,446.43 pence price.
- Confirm the updated total share capital structure (5,822,664,152 issued shares plus 137,008,000 Treasury shares).
- Review the original shareholder authorization from the May 25, 2005 Annual General Meeting to ensure the repurchase volume remains within approved limits.